Physician profile
Jo Andrea Hughes
NPI 1265663371
$814,404.95
in general payments reported to CMS, 2019-2025
34 companies · $271K in 2025
The $271K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $52K · 2022: $143K · 2023: $163K · 2024: $185K · 2025: $271K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $418K · Honoraria: $73K · Travel and Lodging: $61K · Consulting Fee: $43K · Food and Beverage: $25K · Education: $16.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $417,677.00 |
| Honoraria | $72,775.00 |
| Travel and Lodging | $61,287.39 |
| Consulting Fee | $42,577.09 |
| Food and Beverage | $25,133.08 |
| Education | $16.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $465,365.18 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $132,024.98 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Abbvie INC. | $77,182.85 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $69,253.34 | 2021-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $35,849.87 | 2022-2025 | Auvelity, Sunosi |
| E.R. Squibb & Sons, L.L.C. | $11,008.67 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $9,595.31 | 2021-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $6,972.20 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Janssen Scientific Affairs, LLC | $2,343.17 | 2024-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $902.27 | 2022-2025 | Caplyta |
| Tris Pharma INC | $632.62 | 2021-2025 | Dyanavel Xr, Onyda Xr |
| Validus Pharmaceuticals LLC | $507.28 | 2021-2024 | Equetro |
| Janssen Pharmaceuticals, INC | $442.46 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $364.80 | 2021-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Collegium Pharmaceutical, INC. | $298.87 | 2025 | Jornay Pm |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $262.46 | 2023-2024 | Zurzuvae |
| Ironshore Pharmaceuticals INC. | $229.59 | 2024 | |
| Corium, LLC | $208.47 | 2021-2025 | Azstarys |
| Lundbeck LLC | $141.28 | 2021-2025 | Abilify Maintena, Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $124.42 | 2021-2025 | Trintellix |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $114.54 | 2025 | Rejoyn |
| Merck Sharp & Dohme LLC | $92.12 | 2022-2023 | Belsomra |
| Sunovion Pharmaceuticals INC. | $90.48 | 2021-2022 | |
| Bausch Health US, LLC | $69.12 | 2022-2025 | Aplenzin, Wellbutrin |
| Eisai INC. | $64.28 | 2021 | |
| Acadia Pharmaceuticals INC | $42.50 | 2022-2024 | Nuplazid |
| Almatica Pharma LLC | $41.93 | 2021-2022 | |
| Neos Therapeutics, Lp | $39.42 | 2024 | Adzenys Xr-Odt |
| Indivior INC. | $38.74 | 2021 | |
| Vertical Pharmaceuticals, LLC | $30.76 | 2024 | Relexxii |
| Jazz Pharmaceuticals INC. | $22.36 | 2022 | |
| Idorsia Pharmaceuticals US INC | $18.30 | 2023 | Quviviq |
| Tms Neurohealth Centers INC. | $17.20 | 2025 | Tms Neurohealth Centers INC. |
| Avanir Pharmaceuticals, INC. | $13.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jo Hughes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.